These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29032033)

  • 1. Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier.
    Perrone MG; Vitale P; Ferorelli S; Boccarelli A; Coluccia M; Pannunzio A; Campanella F; Di Mauro G; Bonaccorso C; Fortuna CG; Scilimati A
    Eur J Med Chem; 2017 Dec; 141():404-416. PubMed ID: 29032033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid.
    Perrone MG; Miciaccia M; Vitale P; Ferorelli S; Araújo CDCB; de Almeida GS; Souza Domingos TF; da Silva LCRP; de Pádula M; Cabral LM; Sathler PC; Bonaccorso C; Fortuna CG; Scilimati A
    Eur J Med Chem; 2021 Jan; 209():112919. PubMed ID: 33129592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection.
    Scilimati A; Ferorelli S; Iaselli MC; Miciaccia M; Pati ML; Fortuna CG; Aleem AM; Marnett LJ; Perrone MG
    Eur J Med Chem; 2019 Oct; 179():16-25. PubMed ID: 31229884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
    Pati ML; Vitale P; Ferorelli S; Iaselli M; Miciaccia M; Boccarelli A; Di Mauro GD; Fortuna CG; Souza Domingos TF; Rodrigues Pereira da Silva LC; de Pádula M; Cabral LM; Sathler PC; Vacca A; Scilimati A; Perrone MG
    Eur J Med Chem; 2019 Feb; 164():59-76. PubMed ID: 30590258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A further pocket or conformational plasticity by mapping COX-1 catalytic site through modified-mofezolac structure-inhibitory activity relationships and their antiplatelet behavior.
    Solidoro R; Miciaccia M; Bonaccorso C; Fortuna CG; Armenise D; Centonze A; Ferorelli S; Vitale P; Rodrigues P; Guimarães R; de Oliveira A; da Paz M; Rangel L; Sathler PC; Altomare A; Perrone MG; Scilimati A
    Eur J Med Chem; 2024 Feb; 266():116135. PubMed ID: 38219659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).
    Cingolani G; Panella A; Perrone MG; Vitale P; Di Mauro G; Fortuna CG; Armen RS; Ferorelli S; Smith WL; Scilimati A
    Eur J Med Chem; 2017 Sep; 138():661-668. PubMed ID: 28710965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile.
    Abdelazeem AH; El-Saadi MT; Safi El-Din AG; Omar HA; El-Moghazy SM
    Bioorg Med Chem; 2017 Jan; 25(2):665-676. PubMed ID: 27916468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model.
    Perrone MG; Vitale P; Panella A; Fortuna CG; Scilimati A
    Eur J Med Chem; 2015 Apr; 94():252-64. PubMed ID: 25768707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs).
    Perrone MG; Vitale P; Panella A; Ferorelli S; Contino M; Lavecchia A; Scilimati A
    ChemMedChem; 2016 Jun; 11(11):1172-87. PubMed ID: 27136372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.
    Vitale P; Perrone MG; Malerba P; Lavecchia A; Scilimati A
    Eur J Med Chem; 2014 Mar; 74():606-18. PubMed ID: 24531199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors.
    Vitale P; Tacconelli S; Perrone MG; Malerba P; Simone L; Scilimati A; Lavecchia A; Dovizio M; Marcantoni E; Bruno A; Patrignani P
    J Med Chem; 2013 Jun; 56(11):4277-99. PubMed ID: 23651359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diarylheterocycle core ring features effect in selective COX-1 inhibition.
    Perrone MG; Vitale P; Malerba P; Altomare A; Rizzi R; Lavecchia A; Di Giovanni C; Novellino E; Scilimati A
    ChemMedChem; 2012 Apr; 7(4):629-41. PubMed ID: 22278975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.
    Chen Z; Wang ZC; Yan XQ; Wang PF; Lu XY; Chen LW; Zhu HL; Zhang HW
    Bioorg Med Chem Lett; 2015 May; 25(9):1947-51. PubMed ID: 25866240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly Selective Cyclooxygenase-1 Inhibitors P6 and Mofezolac Counteract Inflammatory State both
    Calvello R; Lofrumento DD; Perrone MG; Cianciulli A; Salvatore R; Vitale P; De Nuccio F; Giannotti L; Nicolardi G; Panaro MA; Scilimati A
    Front Neurol; 2017; 8():251. PubMed ID: 28649222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: Molecular docking studies.
    Abdel-Aziz AA; El-Azab AS; Abou-Zeid LA; ElTahir KE; Abdel-Aziz NI; Ayyad RR; Al-Obaid AM
    Eur J Med Chem; 2016 Jun; 115():121-31. PubMed ID: 26999325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal.
    Di Nunno L; Vitale P; Scilimati A; Tacconelli S; Patrignani P
    J Med Chem; 2004 Sep; 47(20):4881-90. PubMed ID: 15369392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
    Abdel-Aziz AA; ElTahir KE; Asiri YA
    Eur J Med Chem; 2011 May; 46(5):1648-55. PubMed ID: 21388719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on SAR Studies Toward New COX-1 Selective Inhibitors.
    Vitale P; Scilimati A; Perrone MG
    Curr Med Chem; 2015; 22(37):4271-92. PubMed ID: 26511468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of 2,3-diaryl-1,3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.
    Zarghi A; Najafnia L; Daraee B; Dadrass OG; Hedayati M
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5634-7. PubMed ID: 17822894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.